[Effectiveness and adequacy of tolvaptan prescription in hospitalized patients]
Purpose:
To analyse the effectiveness of the use of Tolvaptan and the adequacy of Tolvaptan prescription at a tertiary level hospital.
Methods:
Prospective observational study of Tolvaptan prescrip - tion from October of 2010 to December of 2011.
Results:
30 patients (60.0% males) were included, 50.0% of which were diagnosed with heart failure and 30.0% with SIADH. Tolvaptan allowed achieving sodium levels higher than 135 mEq/L in 53.3% of the patients with a mean baseline value of 125.3±7.3 mEq/L. The median treatment duration was 5.0 days (interquartile range=3-45). A significant increase of uric acid associated to Tolvaptan treatment was observed. The prescription was in agreement to what has been established in GFT in 63.3% of the cases.
Conclusions:
Tolvaptan increases sodium levels by 7.5 mEq/L, both in SIADH-associated hyponatremia and in heart failure, with an appropriate safety profile.
Related Concept Videos
Acute Kidney Injury VI: Nursing Management
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Diuretics
Heart Failure VI: Adjunct Therapies
